Best practice in thyroid pathology

C E Anderson, K M McLaren

Thyroid pathology is a specialist area but is often encountered by the general pathologist in a variety of forms including cytology, frozen sections, and resection specimens. In the thyroid gland, as for other endocrine organs, many aspects of diagnosis are unique to this area of histopathology; thus, the aims of this paper are to set out best practice guidelines which, although not entirely comprehensive, will be of practical use.

Most pathology departments receive relatively small numbers of thyroid specimens compared with those from other organ systems, but they are common enough to be dealt with fairly frequently by the general pathologist. Therefore, every pathologist who reports thyroid specimens should have an understanding of the diagnostic peculiarities and pitfalls of thyroid cytology and histopathology.

THE REQUEST FORM
As for any specimen, the request form should be completed in full with patient details and clinical information. The information given should include the results of related biochemical and radiological investigations if applicable, such as thyroid stimulating hormone concentrations, anti-thyroid antibody titres, and ultrasound scan findings.

FINE NEEDLE ASPIRATION
The use of fine needle aspiration (FNA) in the evaluation of a thyroid nodule is a relatively non-invasive technique that can often be diagnostic and may prevent unwarranted surgery. The method of preparation used can give varying cytological appearances and each has advantages and disadvantages. Recently, newer techniques have been developed—for example liquid based cytology, which allow lysis of blood and the preparation of further samples or a cell block for immunocytochemistry. However, the cytological appearances with liquid based cytology are somewhat different to those on conventional smears and further experience of the technique is required. Indeed, one recent study has suggested that liquid based thin layer methods are not ideal for use in thyroid aspirates.1

“The use of fine needle aspiration in the evaluation of a thyroid nodule is a relatively non-invasive technique that can often be diagnostic and may prevent unwarranted surgery”

Regardless of the technique used, an aspirate should only be regarded as adequate if at least six epithelial groups are present. It should be categorised into one of the following five diagnostic groups, as recommended in the forthcoming thyroid cancer minimum data set.

Thy1: non-diagnostic (either because of inadequate cellularity or if technical problems preclude diagnosis).

Thy2: non-neoplastic (features consistent with a multinodular goitre or thyroiditis).

Thy3: follicular lesions, including those where neoplasia cannot be definitely excluded. In particular, a cellular dominant nodule is indistinguishable from a follicular neoplasm and the lesion should be managed as such.

Thy4: suspicious of malignancy.

Thy5: diagnostic of malignancy with unequivocal features of papillary (fig 1), medullary, or anaplastic carcinoma, or of lymphoma or metastasis.

In the case of an aspirate that is predominantly composed of lymphocytes, a diagnosis of Hashimoto’s thyroiditis is supported by the presence of three components; namely, lymphocytes, plasma cells, and oncocytic epithelium, in conjunction with an appropriate clinical history.

THYROID FROZEN SECTIONS
There is still debate concerning the best operative procedure for differentiated thyroid carcinoma. In several centres, lobectomy is chosen for the dominant nodule in multinodular goitre, follicular adenoma, and minimally invasive follicular carcinoma, with total thyroidectomy reserved for widely invasive follicular carcinoma and papillary carcinoma. In some centres, all differentiated thyroid carcinomas are managed by total thyroidectomy. Conversely, a microfocus of papillary carcinoma or an intracystic papillary carcinoma may simply justify long term follow up rather than...

Abbreviations: CK19, cytokeratin 19; FNA, fine needle aspiration
immediate radical surgery. Disagreement also exists over the use of frozen section in the intraoperative assessment of thyroid nodules.

The guidelines of the British Society of Endocrine Surgeons state that a preoperative FNA is desirable in the assessment of every solitary thyroid nodule, and if this is diagnostic of papillary carcinoma, then it is generally agreed that a frozen section is unnecessary. If FNA was not performed or the result was inadequate or only suspicious of papillary carcinoma then a request for a frozen section may result.

The main arguments against performing frozen section are first the cytological appearances, with potentially misleading nuclear optical clarity and difficulty in discerning nuclear grooves and intranuclear protrusions. Second, dissection of the soft, freshly removed gland inevitably causes architectural disruption that can make evaluation of the capsule difficult. Third, a diagnosis of minimally invasive follicular carcinoma is unlikely to be made on a frozen section because this would require the identification of focal capsular or vascular invasion, which may not be present in the section taken. However, in cases where no preoperative diagnosis is available, many surgeons will request a frozen section and each department should come to an agreement on this matter with the local surgical team, perhaps after determining local reliability of FNA and frozen sections.

In our department, we perform frozen sections on solitary thyroid nodules in some circumstances and we follow a protocol that seeks to minimise the problems listed above (fig 2). After routine measurements, the thyroid capsule is inspected and any palpable lesion measured, before taking one complete transection through the lesion. This enables the assessment of encapsulation, solidity, and the degree of cystic change. Although not widely used, a dab imprint of the cut surface is diagnostically valuable, and the cytological information so obtained is helpful in distinguishing a papillary carcinoma from a follicular neoplasm. If it suggests papillary carcinoma, then one confirmatory frozen section is performed. If it suggests a follicular neoplasm, then the specimen should be fixed for subsequent dissection, as described below. In this way, a papillary carcinoma may be diagnosed with confidence and a widely invasive follicular carcinoma distinguished from the benign or minimally invasive counterparts purely on macroscopic inspection accompanied by cytological affirmation that it is a follicular lesion.

**GROSS EXAMINATION**

**Thyroid tumours**

The specimen should be described as a total thyroidectomy, left lobectomy, or right lobectomy (± isthmus). The specimen should be weighed, measured, and then the external appearance described, paying particular attention to whether the capsule is intact. For a total thyroidectomy specimen each lobe should be measured separately.

In most cases, the specimen should then be sectioned horizontally (fig 3). In the case of a probable follicular neoplasm, one author has put forward an alternative way of sectioning in an effort to optimise sampling of the capsule. In this method,
Follicular neoplasms are bisected in the centre and then each half incised at intervals of 2–3 mm in the capsular plane. Each cut should not be completed until the whole lesion has been incised and then the cuts can be continued to free each slice in turn. This method avoids tangential cutting of the capsule and the difficulty encountered when only a small piece of tissue is left to cut.

The site of the tumour should be noted, along with the distance to the nearest excision margin. The size of the lesion must be noted for the pT aspect of pathological staging, taking the size of the largest lesion if more than one is identified. Extension of the tumour beyond the thyroid gland should be noted.

“In papillary carcinoma, the tumour type should be specifically mentioned, because the tall cell, oncocytic, solid, and diffuse sclerosing variants are said to have a worse prognosis than papillary carcinoma of the classic type.”

Representative blocks should be selected based on the probable histological nature of the lesion. It is well recognised that papillary carcinoma can be multifocal and, therefore, if this diagnosis is suspected, the adjacent and opposite lobe should be sampled and any pale areas processed. In a follicular lesion that is not grossly invasive, the interface between the tumour and the capsule and the tumour and the adjacent gland should be extensively sampled to look for capsular and vascular invasion. In large lesions, at least 10 blocks should be taken and small lesions should be processed in their entirety. In medullary carcinoma, the upper part of the lobes should be sampled because the proportion of C cells is greater in this area, and therefore C cell hyperplasia is more likely to be detected.

Any lymph nodes submitted with the specimen should be dissected in the usual way, noting whether they are ipsilateral or contralateral to the tumour, or in the midline.

**Non-neoplastic thyroids**

These specimens should be described, weighed, and sectioned as above. The slices should be carefully examined for the presence of pale foci because incidental carcinomas can be found in Hashimoto’s thyroiditis, multinodular goitre, and Graves’ disease.

**MICROSCOPIC EXAMINATION**

**Thyroid tumours**

Treatment and prognosis are closely related to histological tumour type and accurate staging, and therefore a thorough microscopic examination is essential. For malignant tumours, the information listed in table 1 should be noted and the TNM staging should be recorded.

The diagnosis of papillary carcinoma is based on the identification of true papillary architecture in the classic type, in addition to several well recognised nuclear features (table 2). In particular, care should be taken to assess the nuclear morphology of apparently follicular lesions so that the follicular variant of papillary carcinoma is not overlooked. Clues helpful in identifying the follicular variant (fig 4) include intensely staining colloid with a scalloped outline, and multinucleate giant cells within the follicles. A recent study has described further criteria including the presence of cells with dense, cerebriform nuclei and overall distortion of the follicular architecture. In papillary carcinoma, the tumour type should be specifically mentioned, because the tall cell, solid, and diffuse sclerosing variants are said to have a worse prognosis than papillary carcinoma of the classic type.

Malignant follicular neoplasms should be described as either widely or minimally invasive. A widely invasive follicular carcinoma shows macroscopic invasion or extensive infiltration of the surrounding thyroid parenchyma and vessels microscopically. In contrast, a minimally invasive follicular neoplasm, which has an excellent long term prognosis, is defined as that which shows capsular invasion or invasion of vessels within or adjacent to the capsule. In this regard, the presence of capsular thickening, even focally, is a suspicious feature that should prompt a careful search for...
capsular or vascular invasion. Capsular invasion is defined as complete penetration of the capsule by an invasive tongue of tumour (fig 5) and should not be confused with entrapment of follicles or pseudoinvasion as a result of previous FNA. This last situation is usually associated with inflammation and haemosiderin deposition.

In a case of medullary carcinoma, it is conventional to describe the cellular pattern of the lesion, although this has no known prognostic relevance. The presence of amyloid should be noted because this is thought to be associated with a better prognosis. Confirmation of the nature of the carcinoma by immunocytochemistry for calcitonin and carcinoembryonic antigen is usual, particularly in poorly differentiated lesions, although immunoreactivity for calcitonin may be lost in these cases. All newly diagnosed medullary carcinomas should now be offered genetic testing because of the association with multiple endocrine neoplasia syndromes.

If a tumour is undifferentiated, immunocytochemistry for thyroglobulin and calcitonin should be performed in an attempt to identify a differentiated component. In cases lacking such hormonal expression, cytokeratin markers may at least permit distinction from a sarcoma, and crucially in a lesion of small cell type, from a lymphoma. If lymphoma involving the thyroid is suspected then the appropriate immunocytochemical markers should be selected.

**Immunocytochemistry in solitary thyroid nodules**

The role of immunocytochemistry in the diagnosis of solitary thyroid nodules has developed considerably over the past few years. Several studies have shown that cytokeratin 19 (CK19) is intensely expressed by almost all examples of papillary carcinoma. Its value lies in the distinction between papillary carcinoma and papillary hyperplasia—for example, in a follicular adenoma—although this is compounded somewhat by the finding of focal weak CK19 positivity in some follicular adenomas. Immunocytochemistry for S100 can also be of use because it is typically expressed by papillary carcinomas but not by areas of papillary hyperplasia. The difficulty of an encapsulated nodule showing a follicular growth pattern and focal areas with some but not all of the cytological features of papillary carcinoma is well recognised, and CK19 positivity in these cases lends weight to a diagnosis of the follicular variant of papillary carcinoma (fig 6).

Galectin 3 is a carbohydrate binding lectin that appears to play a role in diverse processes such as embryogenesis, inflammation, apoptosis, and neoplasia. It is expressed in a high proportion of thyroid papillary and follicular carcinomas but is seldom expressed, other than in scattered cells, in follicular adenomas or dominant nodules of multinodular goitre. If the various reports describing this pattern are borne out, this antibody may be of particular value in distinguishing a minimally invasive carcinoma from a cellular follicular adenoma, because galectin 3 positivity would prompt further sampling of the lesion to identify foci of capsular invasion.

The use of CK19 and galectin 3 could potentially be extended to augment the interpretation of a preoperative FNA. The cytological features of a papillary carcinoma may on occasion be focal or subtle, and the expression of CK19 with or without galectin 3 would add weight to the impression (fig 7). The absence or presence of galectin 3 may supplement the cytological features of a follicular neoplasm, with a negative result supporting a benign conclusion.

Obviously, a diagnosis of papillary carcinoma requires the correct nuclear criteria and minimally invasive follicular carcinoma, the correct architectural features. The pattern of expression of CK19 and galectin 3 should therefore be used to supplement the histological impression. A further caveat with the use of these antibodies is that both can be positive in non-neoplastic thyroid epithelium in the context of inflammation. Therefore, it remains to be seen how useful these markers really become in routine practice.
CONCLUSION

The pathology of the thyroid gland presents the pathologist with a particular set of diagnostic problems. If best practice and the minimum data set guidelines are adhered to, the correct diagnosis should be reached in most cases. Newer techniques such as immunocytochemistry can certainly be helpful in more difficult cases but, as in all areas of pathology, histological features take precedence and good communication with the relevant clinical colleagues is paramount.

Authors’ affiliations
C E Anderson, K M McLaren, Department of Pathology, Royal Infirmary of Edinburgh, 51 Little France Crescent, Edinburgh EH16 4SA, UK

REFERENCES
1 Nasuji JF, Tam D, Gupta PK. Diagnostic value of liquid-based (Thinprep) preparations in non-gynaecologic cases. Diagn Cytopathol 2001;24:137–41
7 Pacini F, Alise R, Capezzoni M, et al. Centrolateral papillary thyroid cancer is frequent at completion thyroidectomy with no difference in low and high risk patients. Thyroid 2001;11:877–81
11 Loh KC, Greenspan FS, Gee E. Pathological tumour-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. J Clin Endocrinol Metab 1997;82:5553–62